Intervention Study to Investigate the Effects of ONS Use Among Malaysian Children With Faltering Growth
NCT ID: NCT05193630
Last Updated: 2022-08-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
172 participants
INTERVENTIONAL
2022-07-07
2023-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of an Oral Nutrition Supplement (ONS) in Children.
NCT02056275
The Efficacy of High Density Formula 1.5 kcal/ml or 1 kcal/ml On Catch Up Growth In Growth Faltering Children
NCT06160765
Nutritional Supplementation in Children at Risk of Undernutrition
NCT05437068
the Effect of High Caloric Oral Nutritional Supplements on Growth and Development of Malnourished Children
NCT05911893
Oral Nutritional Supplementation in Children at Risk of Undernutrition
NCT05161000
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
If subjects fulfil all inclusion and exclusion criteria, and if the parent(s) is (are) willing that his/her/their child will participate, he/she/they will be asked to sign the Informed Consent Form (ICF). Baseline evaluation (including history and anthropometric measurement) will be completed prior to randomisation. A block randomisation will be performed to allocate subjects to treatment arm or control arm in 1:1 ratio.
At enrolment, the investigator assesses baseline characteristics, anthropometrics, appetite score, and the number of the child's sick days during the 4 weeks before enrolment. At the end of the visit, the investigator will provide two 3-days feeding diaries (one for baseline and one for Visit 2) and explain how and when these should be completed. The investigator will provide the Milnutri Sure™ product to the parent whose child is in the treatment arm, explain how to use the Milnutri Sure™ and how to apply other feeding advices for the coming 4 weeks until the next visit. For parent whose child is in the control arm, no Milnutri Sure TM product will be given, nevertheless, dietary counselling will be provided by the investigator.
Four, eight and twelve weeks after enrolment, subjects will have clinic visits (Visit 2, 3 and 4) and the anthropometrics, adverse events, appetite score, compliance, and the number of the children's sick days since last visit will be assessed. At the end of the visit the investigator will provide the product to the parents whose children are in the treatment arm, explains how to use it and how to apply other feeding advices for the coming 4 weeks until the next visit. For parents whose children are in the control arm, though no Milnutri Sure TM product will be given, dietary counselling will be provided by the investigator. At week eight (Visit 3), the investigator will also provide a 3-days feeding diary to the parents to be completed just before the twelve-week 12 visit (Visit 4).
In addition to this, at Visit 4 (the End of Study visit after 12 weeks in the study) the investigator will fill out the end of study visit requirements and stops providing study product. The investigator may request for a follow-up visit to monitor and provide medical and dietary counselling to the subject. If necessary, the investigator may prescribe Milnutri Sure ™ or any other growing up milk or nutritional counselling as part of normal practice.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
The subjects in the treatment arm will be given Milnutri Sure TM product with dietary counselling
Milnutri Sure™
Milnutri Sure™, a commercially available oral nutritional support (ONS) product in powder format, for children of 1 y of age and above (1.0 kcal /ml).
For children between 1 and 3 years of age, the recommendation is to use 2 servings per day, and for children from 4 to 6 years of age, the recommendation is to give 3 servings per day. One serving contains of 45 grams of product and 180 ml water.
Control
The subjects in the control arm, no Milnutri Sure TM product will be given, nevertheless, dietary counselling will be provided by the investigator.
Milnutri Sure™
Milnutri Sure™, a commercially available oral nutritional support (ONS) product in powder format, for children of 1 y of age and above (1.0 kcal /ml).
For children between 1 and 3 years of age, the recommendation is to use 2 servings per day, and for children from 4 to 6 years of age, the recommendation is to give 3 servings per day. One serving contains of 45 grams of product and 180 ml water.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Milnutri Sure™
Milnutri Sure™, a commercially available oral nutritional support (ONS) product in powder format, for children of 1 y of age and above (1.0 kcal /ml).
For children between 1 and 3 years of age, the recommendation is to use 2 servings per day, and for children from 4 to 6 years of age, the recommendation is to give 3 servings per day. One serving contains of 45 grams of product and 180 ml water.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Weight at baseline between ≥ -3 and \< -1 SD WHO-score (mild to moderate undernutrition).
3. Informed consent provided.
Exclusion Criteria
2. Known lactose intolerance / cow's milk allergy
3. Use of (other) ONS 1+ (1 kcal/mL) at enrolment and/or during the three months before enrolment
4. Other family member is already participating in this MONS study.
5. Insufficient ability to understand or communicate in English and/or Bahasa Malaysia
6. Participating in any other clinical study
1 Year
6 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universiti Putra Malaysia
OTHER
Danone Specialized Nutrition (M) Sdn Bhd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zurina Zainudin
Role: PRINCIPAL_INVESTIGATOR
Universiti Putra Malaysia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Pengajar Universiti Putra Malaysia
Serdang, Selangor, Malaysia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
ZURINA ZAINUDDIN
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FS21-MONS01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.